HH, G., M, L., SM, E., EEM, E., HM, A., HH, G., & MA, H. (2018). Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries. Dove Medical Press.
Style de citation Chicago (17e éd.)HH, Ghoraba, Leila M, Elgouhary SM, Elgemai EEM, Abdelfattah HM, Ghoraba HH, et Heikal MA. Safety of High-dose Intravitreal Triamcinolone Acetonide as Low-cost Alternative to Anti-vascular Endothelial Growth Factor Agents in Lower-middle-income Countries. Dove Medical Press, 2018.
Style de citation MLA (8e éd.)HH, Ghoraba, et al. Safety of High-dose Intravitreal Triamcinolone Acetonide as Low-cost Alternative to Anti-vascular Endothelial Growth Factor Agents in Lower-middle-income Countries. Dove Medical Press, 2018.